Press release - 04/11/2026 Molecular guardian inhibits aggressive brain tumor's ability to switch between identities One of the reasons for the high aggressiveness of glioblastomas is their remarkable adaptability. A team led by scientists from the German Cancer Research Center (DKFZ), the EMBL, HITBR*, and the Wellcome Sanger Institute, Cambridge, now describes how glioblastoma cells switch between different states. At the same time, they identified a key factor that, acting as a guardian of cell identity, limits this adaptability.
Press release - 02/11/2026 Stem Cells in Deep Sleep as a Secret Reserve Researchers at the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute have discovered a group of particularly long-lived blood stem cells in mice. These cells remain in a dormant state for an exceptionally long time while retaining their ability to generate new blood cells. This newly discovered cell population may be responsible for sustaining blood regeneration and immune defense throughout a mouse’s entire life.
Press release - 02/11/2026 Heidelberger researchers receive Else Kröner memorial fellowships for projects on kidney disease and AI-based diagnostics Why do certain congenital kidney disorders vary so widely in severity among affected individuals? Can AI improve breast cancer diagnostics? These are the questions being addressed in current projects by two early-career researchers at the Heidelberg Faculty of Medicine at Heidelberg University.
Press release - 29/10/2026 New Approach Could Make Immunotherapy for Blood Cancer More Precise Researchers at the Faculty of Medicine – University of Freiburg have developed a new approach to specifically target an aggressive form of blood cancer while better sparing healthy immune cells. In what is known as T-cell acute lymphoblastic leukemia (T-ALL), cancer cells develop from the body’s own immune defense cells. This complicates treatment, as immunotherapies studied to date can also destroy healthy immune cells.
Press release - 29/10/2026 VUSE XR closes €1.2 million pre-seed round to scale enterprise mixed reality training VUSE XR today announced the closing of a €1.2 million pre-seed financing round led by IACD, a Düsseldorf-based business angel network. The company develops the VUSE XR Hub, an enterprise software solution for creating and deploying mixed reality training for industrial and life sciences companies.
Press release - 28/10/2026 A Discovery in Freiburg Makes Cancer Immunotherapy Better Tolerated A discovery made in Freiburg opens up new treatment options for cancer patients worldwide: Researchers at the Medical Center – University of Freiburg have discovered how severe side effects of cancer immunotherapies can be alleviated using a specialized cell therapy involving treated white blood cells.
Press release - 26/10/2026 Multiple sclerosis: New treatment significantly reduces relapses A new treatment could improve care for people with relapsing multiple sclerosis (MS). In two international studies involving a total of 2,007 patients, remibrutinib reduced the annualized relapse rate by 31% to 35% compared with an established MS therapy. New inflammatory brain lesions were also significantly less frequent. In addition, there are indications that the treatment may slow the progression of physical disability.
Press release - 20/10/2026 How randomness makes artificial vision more reliable Humans are usually remarkably good at recognising objects, even under poor viewing conditions. Artificial vision systems, by contrast, reach their limits more quickly when images are distorted or unfamiliar. Researchers at the Hertie Institute for Clinical Brain Research (HIH) have now investigated what artificial vision systems can learn from the brain.
Press release - 19/10/2026 New Biotech Master’s Degree Launches at Ulm University: Pharmaceutical and Molecular Biotechnology How do RNA-, protein- or stem cell-based therapies work? How can data science methods from bioinformatics and artificial intelligence be used to develop new pharmaceutical active substances? Students at Ulm University are learning this in the new master’s programme in Pharmaceutical and Molecular Biotechnology (PMB).
Press release - 16/10/2026 A new approach to osteoporosis treatment Disabling a bone formation inhibiting protein molecule How can the human body be stimulated to build more bone, thus helping those affected by osteoporosis? Researchers in Ulm have investigated the role played by the protein molecule Axl in this process. Their efforts were successful: in a study, they demonstrated that Axl inhibits bone formation – and that cells produce significantly more bone tissue when the molecule is blocked using medication. There are no discernible harmful side effects.
Press release - 16/10/2026 Epilepsy: AI Aims to Improve Treatment with Brain Pacemakers About 250,000 people in Germany live with epilepsy that does not respond adequately to medication. How can their treatment be further improved with a brain pacemaker? As part of the CLOUDIA research project, the Medical Center – University of Freiburg is now collaborating with a medical technology company to develop an AI-supported assistance system for analyzing long-term brain activity data.
Press release - 15/10/2026 Four Million Euros in EU Funding to Improve Prostate Cancer Care A European research consortium led by the German Cancer Research Center (DKFZ) aims to fundamentally improve the diagnosis and treatment of prostate cancer using AI agents, big data, and patient-centered clinical decision support. The central goal is to detect aggressive tumors early and accurately, reduce unnecessary interventions, and tailor treatment decisions more closely to the individual patient.